# Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/APLT/applied-therapeutics-presents-full-12-month-clinical-results-and-new-topline-data-from-inspire-phase-2-3-trial-of-govorestat-in-cmt-sord-in-late-breaking-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting
Ticker: APLT
Company: Applied Therapeutics
Source: Applied Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.appliedtherapeutics.com
## Summary

S lowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the

## Article Body
S lowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the
## Recent Company News
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports First Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-first-quarter-2025-financial-results) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-presents-full-12-month-clinical-results-and-new-topline-data-from-inspire-phase-2-3-trial-of-govorestat-in-cmt-sord-in-late-breaking-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Key Leadership Appointments](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-key-leadership-appointments) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports Second Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-second-quarter-2025-financial-results) — Source: Applied Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)